A Comprehensive Prospective Study of Costs Associated to the Evaluation of beta-lactam Allergy

Running title: Delabelling beta-lactam hypersensitivity

Sobrino-García M1, Muñoz-Bellido F1, Moreno E1,2,3, Macías E1,2,3, Gracia-Bara MT1,2, Laffond E1,2,3, Lázaro-Sastre M1, Martín-García C1, de Arriba-Méndez S1,2,3, Campanón-Toro MV1, Gallardo-Higueras A1, Dávila I1,2,3,4

1Allergy Service, University Hospital of Salamanca, Spain
2Institute for Biomedical Research of Salamanca, IBSAL, Salamanca, Spain
3Department of Biomedical and Diagnostic Sciences, Faculty of Medicine. University of Salamanca, Spain
4Asthma, Allergic and Adverse Reactions (ARADyAL) Network for Cooperative Research in Health of Instituto de Salud Carlos III, Salamanca University Hospital, Salamanca, Spain

Corresponding:
Francisco Javier Muñoz-Bellido
E-mail: fjmbellido@saludcastillayleon.es

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.18176/jiaci.0457
Abstract

**Background:** Being labelled as allergic to penicillin or unverified beta-lactam allergy result in patients receiving broader-spectrum antibiotics that may be more toxic, less effective, and/or with a higher cost.

**Objective:** We aimed to evaluate real costs of beta-lactam allergy evaluation.

**Methods:** A prospective real life observational study designed to evaluate all adult patients that consulted during one year for suspected beta-lactam allergy. Direct and indirect costs were systematically recorded. Direct health costs were calculated by taking into account the number of visits and all complementary and diagnostic tests performed; direct non-health costs by considering the number of visits and the kilometers from their homes to the Allergy Service; and indirect costs by considering the absenteeism.

**Results:** A total of 296 patients with suspected allergy to beta-lactams were evaluated in our outpatient clinic from June 1st, 2017 to May 31th, 2018. Total direct health care costs were €28,176.70, with a mean cost and a standard deviation (SD) of €95.19 (37.20). Direct non-health costs reached €6,551.73, that is €22.13 (40.44) per patient. Indirect health costs reached €20,769.20, with a mean of €70.17 (127.40). In summary, the total cost was €55,497.63, which means a cost per patient of €187.49 (148.14).

**Conclusions:** Even considering all possible costs, the evaluation of beta-lactam allergy is not expensive and can save future expenses due to unnecessary use of more expensive and less effective antibiotics.

**Key words:** Beta-lactam allergy, Delabelling, costs, Pharmacoeconomics, Penicillin allergy evaluation
Resumen

Introducción: Un diagnóstico no verificado de alergia a la penicilina o a los betalactámicos (BL) conlleva que los pacientes reciban antibióticos de amplio espectro, que pueden ser más tóxicos, menos efectivos, y/o de mayor coste.

Objetivo: Evaluar los costes reales de un estudio de alergia a los betalactámicos.

Métodos: Se diseñó un estudio observacional prospectivo en condiciones de práctica clínica habitual en el que se evaluaron todos los pacientes adultos que consultaron por sospecha de alergia a BL durante un año. Los costes directos e indirectos se recogieron sistemáticamente. Los costes directos sanitarios se calcularon teniendo en cuenta el número de visitas y todas las pruebas diagnósticas realizadas; en los costes directos no sanitarios se consideraron el número de visitas y los kilómetros desde el domicilio hasta el Servicio de Alergología; en los costes indirectos se evaluó el absentismo.


Conclusiones: Considerando todos los costes posibles, la evaluación de la alergia a betalactámicos no es cara y puede ahorrar gastos futuros debido a una utilización innecesaria de antibióticos más caros y menos efectivos.

Palabras clave: Alergia a betalactámicos, Desetiquetado, Costes, Farmacoeconomía, Evaluación de alergia a penicilina.
INTRODUCTION

Drug allergy can affect 7-10% of the general population and constitutes a Public Health issue [1-3]. Drugs are also an important cause of anaphylaxis [4]. Beta-lactam antibiotics are the drugs most frequently involved in immunological adverse reactions [5]. Nevertheless, most patients that claim to have beta-lactam allergy are determined not to be allergic after an allergy evaluation [1-3]. Unverified penicillin allergy results in patients receiving broader-spectrum antibiotics that may also be more toxic, less effective, and/or with a higher cost. In addition, the unnecessary use of alternative antibiotics places patients at risk for adverse reactions, treatment failures, and health care-associated infections [6-13].

Blumenthal et al [6] estimated the cost of penicillin allergy evaluation prospectively in 30 outpatients, reaching a cost of $220 the base-case, which includes penicillin skin testing and a 1-step amoxicillin drug challenge, performed by an allergist; even with varied assumptions adjusting for operational challenges, clinical setting, and expanded testing, penicillin allergy evaluation still costs only about $540. This modest investment may be offset for patients treated with costly alternative antibiotics that also may result in adverse consequences.

Rimawi et al [14] studied 146 patients with a history of penicillin allergy and negative skin prick tests (SPTs) that were treated with beta-lactam antibiotics. The SPT-guided antibiotic election for these patients resulted in an estimated annual savings of $82,000.

All these reasons reinforce the need of performing an accurate beta-lactam allergy diagnosis. The aim of this study was to prospectively evaluate the costs associated to a proper evaluation of allergy to beta-lactam antibiotics comprehensively.
METHODS

This is a prospective observational study aimed to evaluate all patients of our outpatient clinic that consulted for suspected beta-lactam allergy. The study lasted from the 1st June 2017 to the 31st May of the following year. The study protocol was approved by the local Ethics Committee (code PI4505/2017).

Inclusion criteria

All patients from 14 year old that attended the Allergy Service outpatient clinic for suspected hypersensitivity reactions to beta-lactam antibiotics in that time period were proposed to participate in the study. All patients who voluntarily agreed to participate in the study signed an informed written consent.

Methodology of the study of beta-lactam allergy

Diagnostic procedures were carried out following the European Network of Drug Allergy/ European Academy of Allergy and Clinical Immunology (ENDA/EAACI) protocol [15,16]. In addition to the anamnesis by the responsible physician, this protocol included the following procedures:

- In vivo tests
  a) Skin prick test (SPT), intradermal and patch tests (see Table 1 in the Supplementary Material).
  b) Single-blind, placebo-controlled exposure tests up to the therapeutic dose with different beta-lactams (see Table 2 in the Supplementary Material).

Usually, the clinical history was done in one visit. Then, the patient had another visit for skin testing and drug challenge. When negative result, if more than 6 months had passed since the reaction, another visit was arranged for re-evaluation (SPT and re-exposure test). In patients with a positive result and depending on it, additional visits could be arranged for challenging with alternative beta-lactams (for example, cephalosporins and/or meropenem in case of patients with amoxicillin selective reactions). All visits were prospectively recorded for each patient. Moreover, the number of visits to our outpatient clinic
changed depending on the type of reaction: immediate reaction (those reactions that appeared within the first hour) or non-immediate reaction (those with a latency period greater than one hour).

- In vitro tests

a) Determination of total IgE and specific IgE in some patients (ImmunoCAP® Thermo Scientific™, Phadia Spain S.L., Barcelona, Spain).

**Data and variables collected**

For data collection, a structured questionnaire was handed out to all patients (see Table 3 in the Supplementary Material). Data obtained was stored in a dissociated database, so patients’ anonymity was guaranteed.

**Assessment of costs**

Data relating to staff, materials and infrastructure costs were provided by the Bureau of Management of the University Hospital of Salamanca.

Data concerning the medication used for the study (consumption and costs) were collected in a structured way; these data were provided by the Hospital Pharmacy Service (see Table 2 in the Supplementary Material).

To assess the costs in monetary terms, the following data were considered:

- Reagents used for skin testing and drugs used for challenge tests.
- Reagents used for laboratory tests.
- Fees of doctors, nurses, auxiliary health personnel and administrative staff.
- Building maintenance expenses (water, electricity, etc.).
- Patients transport to the consultation.
- Loss of working hours.
a) Direct health costs

Direct health costs were calculated taking into account the number of visits, complementary and diagnostic tests performed, and the costs for the personnel and materials used during the study.

In this regard, all the diagnostic tests performed were taken into account: *in vivo* tests (skin tests, patch tests and controlled drug exposure tests) and *in vitro* tests (total and specific IgE) (see Text 1 and Table 4 in the Supplementary Material).

To estimate the costs per patient derived of personal fees, these costs were divided by the global number of patients seen in the outpatient clinic during 2017. As the remuneration of staff in the Spanish National Health Service does not depend on medical acts, it was assumed that the cost of each patient was the same (see Text 1 and Table 5 in the Supplementary Material).

Total amount attributed to the patients of the study, including fees and building maintenance expenses, was proportionally calculated on the basis of total amount attributed to the Allergy Service and the number of visits to the outpatient clinic during this period. This datum was provided by the Hospital Administration (see Table 6 in the Supplementary Material).

b) Direct non-health costs

The direct non-health costs were calculated considering the number of patients visits and the kilometers from their homes to the Allergy Service, estimating a cost of €0.19 per kilometer. This is the amount that Spanish Authorities pay to public officials for the use of their private car and has been considered as locomotion expenses [17]. The most of patients lived in the province of Salamanca that has 331,000 inhabitants.

To attribute this cost to a single patient, the distance from the place of residence to the outpatient clinic was estimated. Patients living in the city of Salamanca, which is a small town of 144,000 inhabitants located in the West of Spain, were considered to had come to the hospital by walk (most of them). It was considered that all the rest of patients living in the province of Salamanca had come by car.
c) Indirect costs

Indirect costs were based on loss of working hours (absenteeism). We obtained this amount taking into account the daily labor costs in the European Union (EU).

The average hourly labor cost in 2018 was estimated at €27.4 in the EU. However, the average masks significant differences between EU Member States, with hourly labor costs ranging between €5.4 in Bulgaria and €43.5 in Denmark (in Spain average labor cost was €21.5) [18].

Gross earnings are the largest part of labor costs. Across EU Member States, the highest national median gross hourly earnings were 15 times higher than the lowest when expressed in euros [18]. Spain ranked number 13 of the 28 countries of the EU both in hourly labour costs as in median gross hourly earnings [18].

Statistical analysis

Data were analyzed using IBM® SPSS Statistics V25.0 (Armonk-IBM Corp., New York, USA) and it was considered a statistically significant result when p<0.05. Quantitative variables were described by means and qualitative variables in terms of relative frequencies. Nonparametric test (Mann-Whitney test) and parametric test (T test independent samples) were used to compare quantitative variables means.
RESULTS

A total of 296 patients with suspected allergy to beta-lactams were evaluated in the Allergy outpatient clinic between June 1st, 2017 until May 31th, 2018. Of these 296 patients, 273 (92.23 %) completed the study.

The percentage of women was 65.54% and the age range between 14 and 91 years. Mean age and standard deviation (SD) was 52 years (20.39) (Median 55 and interquartile range, IQR, 36-69).

The demographic characteristics of the study population are presented in Table 7 in the Supplementary Material.

In 46 out of 296 patients, allergy to beta-lactams was demonstrated, representing 15.54% of cases. Mean and median ages of those who were found to be allergic were 53.22 (19.73) and 57 (IQR, 37-70) years, respectively (values similar to those of all patients studied). Out of the 46 patients that were found to be allergic, 29 (63.04%) had previously had an immediate reaction, 16 had a delayed reaction (34.78%) and in one patient the latency period could not be stablished (2.17%).

Out of these 46 allergic patients, 35 (76.09%) were detected by skin tests (skin prick tests were positive in 5 patients, intradermal tests in 29 patients and one patient had positive patch tests). Of these 35 patients, 23 had had immediate reactions and 12 delayed reactions. Other 6 patients (13.04%) were detected by challenge test: 3 of them had had delayed reactions; 2 of them had had immediate reactions and the remaining one, an unknown reaction. The remaining 5 patients, 10.87%, were considered as allergic by the clinical history (4 and 1 with immediate and delayed reactions, respectively).

Concerning the type of reaction, 23 patients (50%), had had skin reactions (10 immediate and 13 delayed), 20 had had anaphylaxis (43.48%) and the remaining 3 patients (6.52%) had had a respiratory reaction, a cardiovascular reaction and other unknown reaction.

Out of these 46 patients, 29 had amoxicillin selective reactions (63.04%); 24 of these (82.76%) tolerated alternative beta-lactams (cephalosporins and meropenem). In 5 patients, challenges with the alternative antibiotics could not be performed or patients did not accept them.
In addition to the descriptive statistics parameters indicated above, now we comment on some statistical inference results. Percentage of the allergic patients who had an immediate reaction is significantly higher than percentage of those who had a delayed reaction (p-value=0.0263).

We also compared the number of visits of the different groups of patients using the independent-samples bilateral T test, obtaining in the two cases significant differences. In the global sample, the mean number of visits until diagnosis was 2.41 (range 1 to 7). The mean number of visits up to completion of the diagnosis was significantly different in patients that finally had a diagnosis of beta-lactam allergy (2.13) than in patients that did not (2.46) (p=0.039). And the mean number of visits of patients that had had immediate reactions (1.95) and that had had delayed reactions (2.76) was also significantly different (p<0.001).

**Direct health costs**

We calculated the costs for the personnel and of materials used during the study, reaching a total of €20,614.64. Of them €1,413.88 were the cost of materials, whereas 19,200.76 corresponded to health care personnel costs (personnel expenses, including payroll and insurances) (see Table 5 and 6 in the Supplementary Material).

The costs of performing skin tests (267 patients), patch tests (32 patients) and controlled exposure tests (260 patients) were €7160.29. Globally, the costs of beta-lactam drugs used in challenge tests were €831.68; and specific IgE (30 patients) were €401.77, reaching an average amount of €13.39 per patient. Finally, total direct health care costs reached €28,176.70, with a mean cost per patient of €95.19 (37.20) (See Table 1).
Direct non-health costs

With an estimated cost of €0.19 per kilometer [17], direct non-health costs reached €6,551.73 (see Table 1).

Of the 296 patients studied, 146 came to our outpatient clinic from localities different to the hospital setting and it was assumed that they came by car, so the cost per kilometer was applied. The mean number of kilometers traveled per patient to attend all the consultations was 236.18 kilometers (252.18), with a cost per patient of €44.87 (47.92).

Data of travel expenses had a very asymmetrical distribution (see Figure 1 in the Supplementary Material). So, the mean figure of average travel expenses was €22.13 (40.44), although was highly influenced by a few high outliers. The median per patient was €0, due to it should be taken into account that more than half of patients lived in a ranged that allowed them coming to the hospital by walking.

Indirect health costs

We measured indirect health costs taking only into account work absenteeism. Total costs reached €20,769.20 (see Table 1). The mean income loss of the 296 studied patients was €70.17 (127.40).

Nevertheless, only 82 patients (27.70%) of the sample were employed. Analyzing only employed patients, the mean income loss was €253.28 (110.48). Of these 82 patients, those who had had immediate reactions, 23 (28.05%), had an mean income loss of €215.63 (49.09). In the case of patients that had had non-immediate reactions, 43 (52.44%), the mean income loss was €286.11 (124.17), whereas in those whose reaction latency period was unknown, 16 (19.51%), the mean income loss was €219.20 (116.25). Patients who had had delayed reactions had higher income loss than who had had immediate reactions (Man-Whitney’s U one tailed test; p=0.006).
Total costs

In summary, total costs of the study were €55,497.63, with a mean cost of €187.49 (148.14) per patient. (see Table 1). The minimum cost was €31.68, the maximum €789.96.

Distinguishing between patients with positive or negative study results, the mean cost were €184.79 (138.50) and €187.99 (150.40) respectively; these amounts were not significantly different (p-value=0.893). The mean cost in patients with immediate was €152.64 (106.73) and with delayed reactions was €220.48 (171.79). There were statistically significantly different (p-value<0.001) (See Figure 1). And, finally, the mean costs in working [€364.12 (156.38)] and non-working patients [€121.28 (68.18)] were significantly different (p-value<0.001).
DISCUSSION
This is a prospective, real life, one year long, comprehensive study evaluating all direct and indirect health costs of studying 296 patients with suspected beta-lactam allergy. Overall, the mean cost of beta-lactam evaluation was €187.49 per patient, meaning that penicillin allergy evaluation is a non-expensive study. Different costs contributed to the final figure: (i) direct health costs that accounted for more than half, reaching a total per patient of €95.19 (37.20), (ii) direct non health costs per patient that reached €22.13 (40.44) and (iii) indirect costs were based on absenteeism that reached €70.17 (127.40) per patient.

In a prospective study that estimated direct and indirect costs of allergic rhinitis in patients attending specialized clinics performed also in Spain (the FERIN study) [19] the distribution of costs was highly different: indirect costs were almost threefold direct costs (24% vs 76%). This is because, in contrast to drug allergy, in allergic rhinitis presenteeism is important and most part of indirect costs.

To our knowledge there is only one prospective study addressing the costs of penicillin allergy evaluation. Thus, Blumenthal et al [6], who prospectively estimated the cost of penicillin allergy evaluation in 30 outpatients found a cost of $220 for the base-case, which with varied assumptions adjusting for operational challenges, clinical setting, and expanded testing, could reach up to $540.

However, our results are not completely comparable because: (i) the per capita incomes of the United States and Spain are highly different (€53,341 and 25,900 respectively in 2018), (ii) differences in the National Health System (mainly private in the United States versus mainly public in Spain); and (iii) currency exchange, i.e., absolute figures are not the same, (1 EUR=1,1250 USD). In our study not with standing costs also varied between a minimum of €31.68 and a maximum of €789.96.

There were two main factors that influenced the final cost of the study. On the one hand, the type of reaction: we found statistically significant differences between patients that had immediate (€152.64) and delayed reactions (€220.48) with a p-value<0.001. This difference was mainly related to the number of visits (193 –average 1.95- and 383 average 2.76-, respectively). On the other hand, the fact of being
employed or not: costs of absenteeism were only present in patients that worked for hire. Thus, differences between working and non-working patients were also statistically significant, with a p-value < 0.001 reaching an average income loss of €364.12 and €121.28, respectively. Finally, costs were not significantly different in patients that had a final diagnosis of penicillin allergy that in those patients in which beta-lactam allergy was excluded (p=0.893).

The main advantages of performing a study of beta-lactam allergy are de-labelling false penicillin allergic patients and correctly diagnosing patients with a real beta-lactam allergy. We want to emphasize that there was a high prevalence of anaphylaxis in patients with positive results (43.48%). In addition, all of our patients with amoxicillin selective reactions in which a challenge with cephalosporins and meromepen were performed (82.76%) tolerated alternative beta-lactams. So, most patients could benefit from treatments with other beta-lactam, contributing to reduce the serious world health problem of antimicrobial resistance.

All patients mislabeled as allergic to beta-lactams would have received alternative drugs, which are usually less effective clinically and economically. In this way, Picard et al [9] showed that additional antibiotic costs increased in more than $15,000 in 1,738 patients receiving non-beta-lactam antibiotics over one year, and Sade et al [10] identified 38% higher costs for the prescribed antimicrobial treatment regimen to be followed upon discharge. Also, MacLaughlin et al [11] showed that the mean antibiotic cost for patients labelled with beta-lactam allergy was significantly higher compared with those without a beta-lactam allergy ($26.81 vs. $16.28 respectively). Moreover, Sastre et al [20] evaluated 505 hospitalized patients with reported drug hypersensitivity, concluding that changes in drugs increased mean treatment costs 4-fold (range, 2-11; mean, €273.47 per patient per day).

In addition to the economic consequences, treatment with non-beta-lactam antibiotics has multiple clinical implications: higher incidences of *Clostridium difficile*, vancomycin-resistant *Enterococcus*, and methicillin-resistant *Staphylococcus aureus* infections along with an increased number of hospital days at inpatients [7] and readmissions, explained by several options. Alternative therapies often are inferior to
beta-lactams, for example, vancomycin treatment for methicillin-susceptible \textit{S. aureus} bacteremia is more frequently associated with recrudescence of disease [8,12]. Adverse reactions to certain non-beta-lactam antibiotics occur with higher frequency than reactions to beta-lactam agents, which may also contribute to readmission during the course of treatment [13].

In addition, penicillin allergy labelling directly impact on the antimicrobial choice by leading to use of less effective and broader spectrum antimicrobials that are associated with antimicrobial resistance [21,22].

Finally, our study has some limitations. We have made estimates according to the overall number of patients and not by act. This is due to the fact that in the public Spanish National Health Service payment to employees is not dependent of medical acts. In addition, although some estimates have been done considering the whole year 2017 and the studies lasted from June 2017 to May 2018, as the period is also of one year, we believe that the deviation is neglectable. Another limitation of our study is the great number on unemployed patients, which clearly influences indirect costs. We had a total of 105 patients (35.47\%) under 16 years of over 65 years. At these ages, people do not usually work in Spain, so this means that these patients are not employed and therefore, it implies a lower mean global indirect cost in our study. Nevertheless, this is due to the fact that our study is a real-life study. We also provide the costs in working patients notwithstanding.

Finally, from a European perspective it should be taken into account that gross earnings at work are different between the different countries of EU, which implies that the indirect costs are different from other countries [18]. This also affects the total cost of the study.

In summary, in this prospective and comprehensive real-life study, in which direct and indirect health costs of evaluating penicillin allergy were considered in a systematic way in an outpatient clinic in Spain, a complete study reached €187.49 (148.14) per patient. We believe that this is an assumable figure, particularly taking into account the consequences of labeling a patient as allergic to beta-lactam.
Acknowledgments

We thank the nursing staff of the Allergy Service for their collaboration.

FINANCIAL SOURCE STATEMENT

The authors declare that they have no financial sources.

CONFLICT OF INTEREST

The authors have no conflict of interests to declare.
REFERENCES


Table 1. Total costs and percentages disaggregated by items and types of costs.

<table>
<thead>
<tr>
<th>Item</th>
<th>n</th>
<th>Cost (%)</th>
<th>Type of Cost</th>
<th>Total cost (%)</th>
<th>Mean cost (SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skin and patch tests</td>
<td>267</td>
<td>€6,271.99 (11.30)</td>
<td>Direct health costs</td>
<td>€28,176.70 (50.77)</td>
<td>€95.19 (37.20)</td>
</tr>
<tr>
<td>Challenge tests</td>
<td>260</td>
<td>€888.30 (1.60)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Specific IgE</td>
<td>30</td>
<td>€401.77 (0.72)</td>
<td>Direct non-health costs</td>
<td>€6,551.73 (11.81)</td>
<td>€22.13 (40.44)</td>
</tr>
<tr>
<td>Materials</td>
<td>296</td>
<td>€1,413.88 (2.55)</td>
<td>Indirect health costs</td>
<td>€20,769.20 (37.42)</td>
<td>€70.17 (127.40)</td>
</tr>
<tr>
<td>Medical personnel fees</td>
<td>296</td>
<td>€19,200.76 (34.60)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Travel expenses</td>
<td>296</td>
<td>€6,551.73 (11.81)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Loss of working hours</td>
<td>296</td>
<td>€20,769.20 (37.42)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TOTAL</td>
<td></td>
<td>€55,497.63 (100)</td>
<td></td>
<td>€187.49 (148.14)</td>
<td></td>
</tr>
</tbody>
</table>


Figure 1. Total cost per patient (€) according to different variables.

<table>
<thead>
<tr>
<th></th>
<th>Positive result</th>
<th>Negative result</th>
<th>Immediate reaction</th>
<th>Delayed reaction</th>
<th>Working patients</th>
<th>Non-working patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maximum cost</td>
<td>676.59</td>
<td>789.96</td>
<td>434.45</td>
<td>778.2</td>
<td>789.96</td>
<td>430.55</td>
</tr>
<tr>
<td>Minimum cost</td>
<td>55.14</td>
<td>31.68</td>
<td>31.68</td>
<td>31.68</td>
<td>31.68</td>
<td>31.68</td>
</tr>
<tr>
<td>Mean cost</td>
<td>184.79</td>
<td>187.86</td>
<td>152.64</td>
<td>220.25</td>
<td>364.12</td>
<td>121</td>
</tr>
</tbody>
</table>